A Phase 2a dose-escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS-986231 in hospitalized patients with heart failure with reduced ejection fraction

Cristina Tita, Edward M. Gilbert, Adrian B. Van Bakel, Jacek Grzybowski, Garrie J. Haas, Mohammad Jarrah, Stephanie H. Dunlap, Stephen S. Gottlieb, Marc Klapholz, Parag C. Patel, Roman Pfister, Tim Seidler, Keyur B. Shah, Tomasz Zieliński, Robert P. Venuti, Douglas Cowart, Shi Yin Foo, Alexander Vishnevsky, Veselin Mitrovic

Research output: Contribution to journalArticlepeer-review

45 Scopus citations

Fingerprint

Dive into the research topics of 'A Phase 2a dose-escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS-986231 in hospitalized patients with heart failure with reduced ejection fraction'. Together they form a unique fingerprint.

Medicine & Life Sciences